Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of LNP1955 in moderate-to-severe plaque psoriasis
2016-001531-12Phase 2Completed
- Sponsor
- Lupin Limited
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of LNP1955 in plaque psoriasis (2 arms), sponsored by Lupin Limited. Primary endpoint: Primary endpoint: PASI 75 at week 12. Started Jun 2016; status: completed.
02
Drugs
LNP1955
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2016-001531-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001531-12.